166 related articles for article (PubMed ID: 26517374)
1. A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor.
Mao Y; Peng Y; Zeng Q; Cheng L; Wang B; Mao X; Meng K; Liu Y; Lian Y; Li D
PLoS One; 2015; 10(10):e0141464. PubMed ID: 26517374
[TBL] [Abstract][Full Text] [Related]
2. Human platelets express functional thymic stromal lymphopoietin receptors: a potential role in platelet activation in acute coronary syndrome.
Wang B; Peng Y; Dong J; Lin J; Wu C; Su Y; Fang H; Wang L; Huang K; Li D
Cell Physiol Biochem; 2013; 32(6):1741-50. PubMed ID: 24356513
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokine TSLP stimulates platelet secretion and potentiates platelet aggregation via a TSLPR-dependent PI3K/Akt signaling pathway.
Dong J; Lin J; Wang B; He S; Wu C; Kushwaha KK; Mohabeer N; Su Y; Fang H; Huang K; Li D
Cell Physiol Biochem; 2015; 35(1):160-74. PubMed ID: 25591759
[TBL] [Abstract][Full Text] [Related]
4. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the TSLP-TSLPR-LAP signaling between epithelial and dendritic cells through hyperlipidemia contributes to regulatory T-Cell defects in atherosclerotic mice.
Yu K; Dong Q; Mao X; Meng K; Zhao X; Ji Q; Wu B; Zhong Y; Zhu Z; Liu Y; Zhang W; Tony H; Shi H; Zeng Q
Atherosclerosis; 2015 Feb; 238(2):278-88. PubMed ID: 25544178
[TBL] [Abstract][Full Text] [Related]
6. Blockage of thymic stromal lymphopoietin signaling improves acute lung injury in mice by regulating pulmonary dendritic cells.
Pan G; Liang Y; Lu L; Chen X; Wang M; Wang L; Yan C; Zhang W
Int J Clin Exp Pathol; 2015; 8(9):10698-706. PubMed ID: 26617780
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
[TBL] [Abstract][Full Text] [Related]
8. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
9. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
10. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
[TBL] [Abstract][Full Text] [Related]
11. Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice.
Liu X; Zhao G; Yan Y; Bao L; Chen B; Qi R
PLoS One; 2012; 7(5):e36237. PubMed ID: 22662117
[TBL] [Abstract][Full Text] [Related]
12. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery.
Hansson EC; Malm CJ; Hesse C; Hornestam B; Dellborg M; Rexius H; Jeppsson A
Eur J Cardiothorac Surg; 2017 Apr; 51(4):633-637. PubMed ID: 28007881
[TBL] [Abstract][Full Text] [Related]
13. Thymic stromal lymphopoietin is a key cytokine for the immunomodulation of atherogenesis with Freund's adjuvant.
Steinmetz M; Laurans L; Nordsiek S; Weiß L; van der Veken B; Ponnuswamy P; Esposito B; Vandestienne M; Giraud A; Göbbel C; Steffen E; Radecke T; Potteaux S; Nickenig G; Rassaf T; Tedgui A; Mallat Z
J Cell Mol Med; 2020 May; 24(10):5731-5739. PubMed ID: 32285594
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Li H; Guo J; Carlson GF; Teng R
Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
[TBL] [Abstract][Full Text] [Related]
16. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B
Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis.
Preusch MR; Rusnak J; Staudacher K; Mogler C; Uhlmann L; Sievers P; Bea F; Katus HA; Blessing E; Staudacher I
Drug Des Devel Ther; 2016; 10():2691-9. PubMed ID: 27616880
[TBL] [Abstract][Full Text] [Related]
19. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
Xue HJ; Shi J; Liu B; Wang DY; Dong ZX; Guo H; Kong YH; Sheng L; Shao Q; Sun DH; Zhang L; Pan YJ; Dong XW; Li JQ; Xue JY; Zhou YY; Yang HP; Li Y
Platelets; 2016 Jul; 27(5):440-5. PubMed ID: 26830862
[TBL] [Abstract][Full Text] [Related]
20. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
